SCOPUS 정보 검색 플랫폼

JAMA

Volumn 310, Issue 10, 2013, Pages 1068-1069

Scalp pustules in a patient receiving chemotherapy

(2) Chiu, Hsien Yi a Chiu, Hsien Ching a

a NATIONAL TAIWAN UNIVERSITY HOSPITAL (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ERLOTINIB; GEFITINIB; POTASSIUM HYDROXIDE;

ACNE; AGED; ARTICLE; CANCER CONTROL; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; HAIR LOSS; HUMAN; LUNG ADENOCARCINOMA; MALE; PARONYCHIA; PRIORITY JOURNAL; PRURITUS; PUSTULE; TREATMENT DURATION;

EID: 84883664698 PISSN: 00987484 EISSN: 15383598 Source Type: Journal
DOI: 10.1001/jama.2013.276214 Document Type: Article

Times cited : (1)

References (10)

1
- 69149096621
- Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors
- Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009;161(3):515-521.
- (2009) Br J Dermatol , vol.161 , Issue.3 , pp. 515-521
- Osio, A.¹ Mateus, C.² Soria, J.C.³

2
- 33749018219
- Mechanisms of cutaneous toxicities to EGFR inhibitors
- DOI 10.1038/nrc1970, PII NRC1970
- Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803-812. (Pubitemid 44450468)
- (2006) Nature Reviews Cancer , vol.6 , Issue.10 , pp. 803-812
- Lacouture, M.E.¹

3
- 84863424046
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer. 2012;20(5):909-921.
- (2012) Support Care Cancer , vol.20 , Issue.5 , pp. 909-921
- Peuvrel, L.¹ Bachmeyer, C.² Reguiai, Z.³

4
- 0142055937
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
- DOI 10.1001/jama.290.16.2149
- Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149-2158. (Pubitemid 37432975)
- (2003) Journal of the American Medical Association , vol.290 , Issue.16 , pp. 2149-2158
- Kris, M.G.¹ Natale, R.B.² Herbst, R.S.³ Lynch Jr., T.J.⁴ Prager, D.⁵ Belani, C.P.⁶ Schiller, J.H.⁷ Kelly, K.⁸ Spiridonidis, H.⁹ Sandler, A.¹⁰ Albain, K.S.¹¹ Cella, D.¹² Wolf, M.K.¹³ Averbuch, S.D.¹⁴ Ochs, J.J.¹⁵ Kay, A.C.¹⁶

5
- 0012381722
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
- DOI 10.1200/JCO.2003.10.038
- FukuokaM, Yano S, Giaccone G, et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (the IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21(12):2237-2246. (Pubitemid 46621858)
- (2003) Journal of Clinical Oncology , vol.21 , Issue.12 , pp. 2237-2246
- Fukuoka, M.¹ Yano, S.² Giaccone, G.³ Tamura, T.⁴ Nakagawa, K.⁵ Douillard, J.-Y.⁶ Nishiwaki, Y.⁷ Vansteenkiste, J.⁸ Kudoh, S.⁹ Rischin, D.¹⁰ Eek, R.¹¹ Horai, T.¹² Noda, K.¹³ Takata, I.¹⁴ Smit, E.¹⁵ Averbuch, S.¹⁶ Macleod, A.¹⁷ Feyereislova, A.¹⁸ Dong, R.-P.¹⁹ Baselga, J.²⁰ more..

6
- 68349139865
- Clinical significance of skin toxicity due to EGFR-targeted therapies
- published online June 22, 2009 doi:10.1155/2009/849051
- Giovannini M, Gregorc V, Belli C, et al. Clinical significance of skin toxicity due to EGFR-targeted therapies [published online June 22, 2009]. J Oncol. doi:10.1155/2009/849051.
- J Oncol
- Giovannini, M.¹ Gregorc, V.² Belli, C.³

7
- 21344462378
- Cutaneous side-effects of kinase inhibitors and blocking antibodies
- DOI 10.1016/S1470-2045(05)70243-6, PII S1470204505702436
- Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491-500. (Pubitemid 40903630)
- (2005) Lancet Oncology , vol.6 , Issue.7 , pp. 491-500
- Robert, C.¹ Soria, J.-C.² Spatz, A.³ Le, C.A.⁴ Malka, D.⁵ Pautier, P.⁶ Wechsler, J.⁷ Lhomme, C.⁸ Escudier, B.⁹ Boige, V.¹⁰ Armand, J.-P.¹¹ Le, C.T.¹²

8
- 33745815322
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
- DOI 10.1016/j.jaad.2005.12.016, PII S0190962205047444
- Graves JE, Jones BF, Lind AC, Heffernan MP. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J AmAcad Dermatol. 2006;55(2):349-353. (Pubitemid 44038007)
- (2006) Journal of the American Academy of Dermatology , vol.55 , Issue.2 , pp. 349-353
- Graves, J.E.¹ Jones, B.F.² Lind, A.C.³ Heffernan, M.P.⁴

9
- 37349120373
- Erlotinib-associated alopecia in a lung cancer patient [2]
- DOI 10.1097/JTO.0b013e31815ba7f9, PII 0124389420071200000017
- Costa DB, Kobayashi S, Schumer ST. Erlotinib-associated alopecia in a lung cancer patient. J Thorac Oncol. 2007;2(12):1136-1138. (Pubitemid 350307913)
- (2007) Journal of Thoracic Oncology , vol.2 , Issue.12 , pp. 1136-1138
- Costa, D.B.¹ Kobayashi, S.² Schumer, S.T.³

10
- 84870829158
- Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor
- Shin JU, Park JH, Cho BC, Lee JH. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor. Dermatology. 2012;225(2):135-140.
- (2012) Dermatology , vol.225 , Issue.2 , pp. 135-140
- Shin, J.U.¹ Park, J.H.² Cho, B.C.³ Lee, J.H.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.